4 completed, 3 recruiting, 2 terminated, 2 unknown. 3 Phase 2, 1 Phase 1, 1 Phase 3, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Completed 3 |
| Phase 1 | 1 | Terminated 1 |
| Phase 3 | 1 | Completed 1 |
| Phase 4 | 1 | Recruiting 1 |
Follow Protein-Losing Enteropathies: new trials by email Literature Review of Protein-Losing Enteropathies trials Research Report on Protein-Losing Enteropathies
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Test the Safety of Pozelimab in Pediatric Participants 1 to 5 Years of Age With a Rare Disease Called CHAPLE (Complement Hyperactivation, Angiopathic Thrombosis, Protein-losing Enteropathy) Disease Pozelimab - CHAPLE Disease | Phase 4 | Recruiting | Regeneron Pharmaceuticals | 5 | 2026-03-19 | 2026-04-13 |
| European Registry Study on Lymphatic Interventions Lymphatic intervention - Lymphatic Disorders, Plastic Bronchitis | Recruiting | Copenhagen University Hospital, Rigshospitalet | 500 | 2026-02-01 | 2026-01-21 | |
| 68Ga-HSA PET/CT Imaging for Protein-losing Enteropathy 68Ga-HSA - Cancer | Not yet recruiting | Peking University Cancer Hospital & Institute | 50 | 2025-05-01 | 2024-12-04 | |
| A Prospective Natural History Study of Lymphatic Anomalies Lymphatic Diseases, Lymphatic Abnormalities | Recruiting | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | 1200 | 2023-03-20 | 2026-10-21 | |
| Camostat Mesylate for Protein-losing Enteropathy After Fontan Operation Camostat mesylate - Fontan Operation, Protein-Losing Enteropathy | Phase 2 | Completed | Seoul National University Hospital | 19 | 2022-10-03 | 2024-12-03 |
| Open-Label Efficacy and Safety Study of Pozelimab in Patients With CD55-Deficient Protein-Losing Enteropathy (CHAPLE Disease) Pozelimab - CD55-deficient Protein-losing Enteropathy, CHAPLE | Phase 2 / Phase 3 | Completed | Regeneron Pharmaceuticals | 10 | 2020-01-27 | 2025-08-29 |
| Characterizing the Effect of Dopamine on Markers of Lymph Re-circulation in Fontan-associated Protein-losing Enteropathy Dopamine, Protein-Losing Enteropathies | Terminated | University of Michigan | 3 | 2019-04-09 | 2026-07-14 | |
| Transcriptome and Metabolic Analyses of CHAPLE Disease Eculizumab Injection - CD55 - Cluster of Differentiation Antigen 55 Deficiency, Primary Intestinal Lymphangiectasis | Unknown | Marmara University | 60 | 2018-06-15 | 2019-08-14 | |
| Inhaled Tissue Plasminogen Activator for Acute Plastic Bronchitis Treatment-inhaled tPA - Plastic Bronchitis, Protein-Losing Enteropathies | Phase 2 | Completed | University of Michigan | 40 | 2018-03-19 | 2025-08-19 |
| Lymphatic Morphology of Fontan Patients Non-contrast MRI, Cardiopulmonary exercise test - Lymphatic Abnormality, Plastic Bronchitis | Completed | University of Aarhus | 41 | 2018-01-01 | 2023-06-18 | |
| Pilot/Ph I Safety and Efficacy of ODSH in Protein Losing Enteropathy Secondary to Single Ventricle Palliative Surgery ODSH at 0.125 mg/kg/h, ODSH at 0.375 mg/kg/h, ODSH at 0.250 mg/kg/h - Protein Losing Enteropathy | Phase 1 | Terminated | Jazz Pharmaceuticals | 5 | 2010-07-01 | 2021-12-02 |
| International Lymphatic Disease and Lymphedema Registry Lymphedema | Unknown | Stanford University | 5000 | 2009-03-01 | 2023-11-22 | |
| Compassionate Use of Pozelimab Pozelimab - CD55-deficient Protein-losing Enteropathy | Approved for marketing | Regeneron Pharmaceuticals | 2025-11-10 |
Heart Defects, Congenital (3) · Lymphatic Abnormalities (3) · Lymphatic Diseases (3) · Lymphangiectasis (2) · Lymphedema (2) · Univentricular Heart (2) · Chylothorax (1) · Chylous Ascites (1) · Neoplasms (1) · Osteolysis, Essential (1) · Vascular Malformations (1) · Waldmann disease (1)
Digestive System Diseases (13) · Gastrointestinal Diseases (13) · Intestinal Diseases (13) · Congenital Abnormalities (6) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (6) · Cardiovascular Abnormalities (4) · Cardiovascular Diseases (4) · Hemic and Lymphatic Diseases (4) · Heart Diseases (3) · Bone Diseases (1) · Bone Diseases, Developmental (1) · Bone Resorption (1) · Lymphatic Diseases (1) · Musculoskeletal Diseases (1) · Osteolysis (1)
Exercise Test (1) · KPNA1 protein, human (1) · Tissue Plasminogen Activator (1) · camostat (1) · eculizumab (1)
Regeneron Pharmaceuticals (3) · University of Michigan (2) · Copenhagen University Hospital, Rigshospitalet (1) · Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) (1) · Jazz Pharmaceuticals (1) · Marmara University (1) · Peking University Cancer Hospital & Institute (1) · Seoul National University Hospital (1) · Stanford University (1) · University of Aarhus (1)
United States (6) · Turkey (Türkiye) (3) · Denmark (2) · China (1) · South Korea (1) · Thailand (1)
Gi Beom B Kim (1) · Hua Zhu (1) · Joshua Meisner, MD, PhD (1) · Kathleen A Stringer, PharmD (1) · Kurt Schumacher, MD, MS (1) · Mark Russell, MD (1) · Michael J Lenardo, M.D. (1) · Michael Rahbek Schmidt, Ass. professor, PhD, DMSc (1) · Sarah E Sheppard, M.D. (1) · Stanley G Rockson (1) · Vibeke E Hjortdal, Professor (1)
PMID 38278170, PMID 39118150, PMID 39657032, PMID 39934837, PMID 40227431, PMID 40910281
ZIAAI000717-22 (1)